http://sgc.anlis.gob.ar/handle/123456789/12 INP 2026-05-09T08:59:15Z http://sgc.anlis.gob.ar/handle/123456789/2739 Title: Mammal ectoparasites in the Global South: Climate-driven threats to human and other animal health Authors: Leonardi, Maria Soledad; Sanchez, Juliana P; Laroche, Maureen; Weeks, Emma 2026-01-01T00:00:00Z http://sgc.anlis.gob.ar/handle/123456789/2732 Title: Trypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency Authors: Perrone, Alina E.; Pinillo, Mariana; Rial, Marcela Silvina; Fernandez, Marisa; Milduberger, Natalia; González, Carolina; Bustos, Patricia L.; Fichera, Laura E.; Laucella, Susana A.; Albareda, María Cecilia; Bua, Jacqueline Abstract: Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma cruzi, the causative agent of Chagas disease, has a 19-kDa cyclophilin, TcCyP19, that was found to be secreted in parasite stages of the CL Brener clone and recognized by sera from T. cruzi-infected mice and patients. The levels of specific antibodies against TcCyP19 in T. cruzi-infected mice and subjects before and after drug treatment were measured by an in-house enzyme linked immunosorbent assay (ELISA). Mice in the acute and chronic phase of infection, with successful trypanocidal treatments, showed significantly lower anti-TcCyP19 antibody levels than untreated mice. In children and adults chronically infected with T. cruzi, a significant decrease in the anti-TcCyP19 titers was observed after 12 months of etiological treatment. This decrease was maintained in adult chronic patients followed-up 30–38 months post-treatment. These results encourage further studies on TcCyP19 as an early biomarker of trypanocidal treatment efficiency. 2023-07-25T00:00:00Z http://sgc.anlis.gob.ar/handle/123456789/2712 Title: Economic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the RAISE study Authors: Viegas Andrade, Monica; de Souza Noronha, Kenya Valeria Micaela; de Souza, Aline; Abreu Julião. Nayara; Motta-Santos, André Soares; Franco Braga, Paulo Estevão; Bracarense, Henrique; Alves do Santos, André Batista; Ramos Nascimento, Bruno; Machado,Ísis Eloah; Martins-Melo, Francisco Rogerlândio; Molina, Israel; Perel, Pablo; Geissbühler, Yvonne; Demacq, Caroline; Castro Jaramillo, Hector Eduardo; Echeverria, Luis E; Principato, Mario Bruno; Aguilera Mora, Luisa Fernanda; Fernandez, Marisa; Nina Calisaya, Jhonatan Jhimmy; Pinho Ribeiro, Antonio Luiz Abstract: Background Chagas disease (ChD) remains a public health concern in Latin America. Despite a decline in overall prevalence, the chronic symptomatic forms still impose a substantial epidemiological and economic burden. This study undertakes a comprehensive, population-based cost analysis of chronic Chagas disease (CCD) from a societal perspective in seven endemic Latin American countries for 2010 and 2023. Methods A Markov model with one-year cycles and six states was employed. Direct medical and indirect costs, converted to 2024 purchasing power parity US dollars, were estimated using prevalence data from the Global Burden of Disease Study 2023. Based on a previous Brazilian Markov model, parameters were adjusted using healthcare coverage and per capita health expenditure ratios for each country, further validated by national experts. Findings In 2010, Brazil (US$252 billion) and Argentina (US$164 billion) had the highest lifetime burdens. As a percentage of annual Gross Domestic Product, Bolivia (0⋅9%) and Argentina (0⋅8%) were most affected. CCD accounted for 6% of total health expenditures in both countries. Between 2010 and 2023, most countries experienced a decline in economic burden due to decreased CCD prevalence, despite an increased proportion of patients with cardiac conditions, reflecting population aging and disease progression 2026-02-01T00:00:00Z http://sgc.anlis.gob.ar/handle/123456789/2711 Title: Evaluación comparativa de pruebas de ensayo de diagnóstico rápido (PDR) que detectan anticuerpos humanos específicos contra Trypanosoma cruzi para apoyar la detección de casos de Enfermedad de Chagas en Argentina Authors: Instituto Nacional de Parasitología (INP) 2025-05-01T00:00:00Z